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Abstract 
Background: Squamous cell carcinoma of the oral cavity (SCCOC) is the dominant origin of cancer associated 
mortality. Previous findings by our study reported that acquisition of anoikis resistance has a significant role in tumor 
progression of oral cavity. Several genes were over-expressed in anoikis-resistant cells under detached conditions 
which we confirmed earlier by microarray. Normal oral squamous epithelia grow adherent to a basement membrane, 
and when detached from the extracellular matrix, undergoes programmed cell death. The acquisition of anoikis-resist-
ance is crucial phenomena in oral tumor advancement. In the current study, we have identified S100A7 expression 
as contributing factor for anoikis resistance and tumorigenicity in human oral cancer cells. Further, we have explored 
that elevated S100A7 expression in anoikis-sensitive oral keratinocytes and cancer cells reshape them more resistant 
to anoikis and apoptosis inducers via activation of cellular intrinsic and extrinsic avenue.
Methods: A subset of human cancer cell lines TU167, JMAR, JMARC39, JMARC42 and MDA-MB-468 were utilized for 
the generation of resistant stable cell lines. Further, immunohistochemistry, western blot and immunoprecipitation, 
assays of apoptosis, soft agar assay, orthotopic animal model and signaling elucidation were performed to establish 
our hypothesis.
Results: S100A7 gene is found to be responsible for anoikis resistance and tumorigenicity in human oral cancer cells. 
We have observed up-regulation of S100A7 in anoikis resistant cell lines, orthotropic model and patients samples with 
head and neck cancer. It is also noticed that secretion of S100A7 protein in conditioned medium by anoikis resist-
ant head & neck cancer cell and in saliva of head and neck cancer patients. Up-regulation of S100A7 expression has 
triggered enhanced tumorigenicity and anchorage-independent growth of cancer cells through Akt phosphorylation 
leading to development of aniokis resistance in head and neck cancer cells.
Conclusions: These data have led us to conclude that S100A7 is the major contributing factor in mediating anoikis-
resistance of oral cancer cells and local tumor progression, and S100A7 might be useful as diagnostic marker for early 
detection of primary and recurrent squamous cell cancer.
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Background
Cells undergo anchorage-independent cell death or an 
anoikis, as they separate and move towards the epithelial 
surface [1, 2]. Anoikis has a specific kind of physical char-
acteristics similar to apoptosis, and it plays a crucial role 
in maintenance of normal tissue homeostasis and cell 
replacement [2]. Anoikis occurs due to the inappropri-
ate or faulty cellular interaction between Cell and ECM 
that might lead to the prevention of detached cells to the 
improper location. The current knowledge suggested 
that keratinocytes underwent anoikis when these normal 
cells failed to attach to ECM [3]. Anoikis has a dominant 
involvement in the safeguard mechanisms of epithe-
lial cells when they are in adherent culture, depending 
upon the interaction with ECM proteins. Due to anoikis 
resistance, some oral cavity cancer cell lines can grow in 
suspension due to the altered regulation of integrin and 
E-cadherin directed survival signaling [4, 5].
Anchorage-independent cell growth is an important 
physiological process for cancer development. To assess 
the tumorigenicity, the unique property of tumor cells 
to grow in soft agar was considered as an in vitro test in 
immunosuppressed animals [6]. During anoikis cells are 
detached from the ECM by mechanical forces or some 
other means to undergo apoptosis by extrinsic and intrin-
sic pathways. Failure to undergo anchorage-independent 
cell growth can be as an important hallmark of cancer 
owing to its property of invading through blood vessels 
and lymphatic stream. In order to support this fact, there 
are evidences that the passage of non-oncogenesis mon-
key kidney epithelial cells in suspension culture formed 
an anoikis-resistant line which leads to the generation of 
hypodermic tumors in nude mice [7]. Moreover, mela-
noma cell suspension culture exhibited anoikis resistance 
and metastasis, when administered through tail veins of 
mice [8]. While these earlier findings are supportive of 
our hypothesis, the correlation of in vitro anoikis resist-
ance and metastasis potential has not been yet confirmed 
in an orthotropic in  vivo tumor model. Literature sug-
gested the involvement of TrkB protein in regulation of 
metastasis by screening of anoikis. In this current study, 
suitable experimental design and tumor model were 
developed to prove our hypothesis.
Psoriasin (S100A7), which belongs to S100 gene fam-
ily [9], was first isolated from psoriasis affected skin [10]. 
It is an 11.4 kDa secretary protein, often responsible for 
inflammatory responses in the skin [11, 12]. Furthermore, 
altered keratinocyte differentiation in skin was observed 
[13, 14], and the differential expression of psoriasin was 
noted in squamous cell cancer (SCC) of bladder [15] and 
in breast carcinoma [16, 17]. Intensive studies revealed 
that increasing expression of psoriasin was well associ-
ated with early development of oncogenesis. Psoriasin 
was found to be up regulated in ductal carcinoma, but 
the expression of this protein was relatively low in adja-
cent invasive carcinoma [17]. The altered expression of 
psoriasin was associated with epithelial cell differentia-
tion. S100A2 and S100A4, member of S100 gene family 
were found to be deregulated in breast cancer [18, 19]. 
Distinct changes in the expression profile of psoriasin 
were also noticed in benign tumors and high-grade DCIS 
[17, 20]. Altered expression of psoriasin also appeared 
to be associated with poor prognosis in several invasive 
tumor predominantly in ERα-ve and ERß-ve tumors [21]. 
Previous studies suggested that unlike the other category 
of S100 proteins counterpart, here psoriasin expres-
sion is generally controlled to the epithelial part of skin, 
breast, and bladder [11, 15, 21–23]. In hyperplasia and 
dysplasia mediated pathological conditions, the expres-
sion of psoriasin was relatively low in normal epithelial 
cells whereas it was mostly up-regulated in keratinocytes 
in the epidermis. Earlier report revealed that functional 
activity of psoriasin is regulated by a small cluster of 
gene. Serial analysis of gene expression (SAGE) profiling 
demonstrated that above gene population is significantly 
up-regulated in actinic keratosis compared to normal 
skin [13]. Only some of the genes, like psoriasin, were 
being expressed in the ‘epithelial differentiation com-
plex’ region on chromosome 1q21 [24]. It was observed 
that the main cellular transformation behind invasive 
phenomena is dedifferentiation that is involved as an 
integral part of this process [25]. Several important fac-
tors were found to participate in controlling the regula-
tion of psoriasin. Vitamin A derived metabolite retinoic 
acid included among these factors, which was found to 
be closely associated with the control of squamous cell 
differentiation [26]. Psoriasin regulating factors include 
irradiation by UV, calcium and altered cell attachment to 
the skin [26–30] and various physiological factors such as 
confluency, growth factor deprivation and loss of cellu-
lar attachment in breast epithelial cells [16, 20]. Further 
evidences confirmed that cell stress due to UV radiation 
promotes activation of AP-1 transcription factor com-
plex mediated by c-Jun/JNK pathway [31]. It was noticed 
that skin tumorigenesis, progression, and invasion are 
caused due to the stimulation of the AP-1 pathway [32]. 
Our study is trying to establish the importance of psoria-
sin in anoikis resistance and head and neck cancer tumor 
progression.
Results and discussion
Identification of psoriasin (S100A7) as a regulatory gene
In an attempt to recognize genes whose appearance might 
be modulated in the human head and neck cancer cells, we 
have used microarray techniques. Initially, two cell lines: 
TU167 (less invasive) and JMAR (highly invasive) were 
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cultured at both attach or detached condition for 24 and 
48 h, total RNA was isolated, and cDNA probes were pre-
pared using reverse transcription. Later, sequencing and 
comparison of the cDNA revealed that it was found to be 
100% identical to human S100A7 [33]. To determine the 
expression of S100A7, cells were grown in suspension for 
24 and 48 h, and the protein expressions were evaluated by 
western blot. As shown in Fig. 1a, S100A7 protein expres-
sion was up-regulated during detachment of JMAR C39 and 
JMAR C42 anoikis resistant cell line (soft agar clone derived 
from JMAR) and not in TU167, anoikis sensitive cell line 
indicating that S100A7 is one of the up-regulated genes 
responsible for anoikis resistance and tumor progression. 
S100A7 level was also observed to be up-regulated during 
anoikis in JMAR cells as shown by immunofluorescence 
microscopy (Fig.  1b). Further, TUNEL (Terminal deoxy-
nucleotidyl transferase dUTP nick end labelling) assays 
were performed which shows increasing number of anoikis 
resistance cells (Fig.  1c). In the direction of confirmation 
of S100A7 gene was controlled by anoikis in HNSCC cells, 
regulation of the S100A7 gene expression was verified by 
experiments involving Northern blot analysis (Fig.  1d) 
showing the up-regulation of S100A7 mRNA in JMAR, 
JMARC39 (another soft agar clones derived from JMAR) 
and JMAR C42 during detached condition.
Expression of the S100A7 in an orthotopic tumor model 
of squamous cell oral cancer
On the way to assess the property of tumor progres-
sion due to the selection for anoikis resistance, we have 
Fig. 1 Up-regulation of S100A7 protein and mRNA during detachment of anoikis resistant cell lines and in orthotopic mice model. a Both the 
attached and detached at different time points of cell lysates of TU167 and JMAR were analyzed by western blot for S100A7. β-actin was used 
as a loading control. b Detection of S100A7 in JMAR detached cells by immunofluorescence after staining with anti-S100A7. c TUNEL (Terminal 
deoxynucleotidyl transferase dUTP nick end labelling) assays were performed to study increasing anoikis resistance cells. d Northern blot showing 
expression of S100A7 mRNA in TU167 and various clones of JMAR in both attached and detached condition for indicated time intervals. e IHC of 
S100A7 expression for FFPE tumor sections of mice generated from orthotopic injection of TU167 and JMAR cell lines.
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studied in  vivo orthotopic tumor model with both the 
cells [26]. In the consequent experiment, TU167 or 
JMAR cells (5 × 105) were injected in the tongues of the 
mutant (the nude) mice, which lead to tumor forma-
tion and weight loss in the animals. The development of 
tumors was also observed in both the groups in 100% of 
the animals, the rates of continued existence (animals 
were sacrificed till the body weight loss was found less 
than 25% from the starting experiment weight) variation. 
But, it was apparently noticed that the average survival 
time was 17 days for the JMAR animals, in comparison 
to all other animals which were dying by the end of the 
23rd day of the trial. The tumor formation by both the 
cells was histologically distinct by the end of 31 days. It 
was also observed that one hundred percentages of the 
TU167 animals existed with negligible mass drop, apart 
from pathologically apparent and morphologically con-
firmed tongue tumors. Tumor formation caused by 
TU167 cells showed quite a lot of well-contained tumor 
layers, while JMAR tumors displayed an extraordinary 
spreading infiltrative development style. Further inves-
tigation by immunohistochemistry of tumor sections 
showed more positive and intense staining of S100A7 in 
JMAR bearing orthotopic tongue tumor as compared to 
TU167 (Fig. 1e). Taken together, our findings suggest that 
S100A7 is responsible for more tumorigenicity and likely 
to be anoikis resistance.
Expression of the S100A7 in the human head and neck 
cancer specimens
We had immunostained tissue specimens of differ-
ent malignant tumor regions of head and neck cancer 
specimens as well as a normal epithelium region with 
an anti-S100A7 rabbit antibody. Here, IHC sections of 
normal and tumor specimens (Fig. 2a) demonstrate that 
psoriasin is up-regulated in association with head and 
neck tumorigenesis. In the direction of exploring the 
significance of S100A7 in head and neck tumors, we 
studied whether S100A7 protein was changed in corre-
sponding adjacent non-cancerous human epithelium and 
Fig. 2 Expression of S100A7 in the human head and neck tumor. a Representative immunohistochemical staining for S100A7 in tissues from 
normal and tumor sections. b Paired head and neck tumors (T) and adjacent normal (N) tissue were analyzed by immunoblotting with the indi-
cated antibodies. c Immunohistochemical staining for S100A7 in tissues from normal and tumor sections in 42 samples and their correlation with 
tumorigenesis in table form.
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cancer tissue biopsy samples. As it is presented in Fig. 2b, 
S100A7 expression was elevated in 8 out of 12 tumor 
samples (66.66%) as evaluated with the neigh boring non-
cancerous tissue, which illustrate either or no expression 
of S100A7. The loading control was used as β-actin for 
the blots that were used after reprobing. Psoriasin, pro-
tein expression was further evaluated by IHC in human 
tumor and normal oral tissue samples. The prevalence of 
S100A7 expression in these patients was 90.47% (38/42) 
as shown in Fig. 2c. Hence, we have analyzed ten normal 
oral samples for S100A7 expressions by IHC that shows 
negligible expression. A possible role of S100A7 in medi-
ating invasion remains to be explored in future.
Secretion of the S100A7 protein in conditioned medium 
by anoikis resistant head and neck cancer cell and in saliva 
of head and neck cancer patients
To validate S100A7 as a biomarker for head and neck 
squamous cell carcinoma, S100A7 protein that got 
released in saliva by the patients or secreted in the con-
ditioned medium by HNSCC cell lines were analyzed 
by Immunoblot. We had grown TU167 and JMAR cell 
in attached and detached condition. Later, condition 
medium containing equal amount of protein were immu-
noprecipitated and immunoblotted with S100A7 anti-
body. As shown in Fig.  3a, JMAR cell secreted S100A7 
but not TU167 (anoikis sensitive cell line).We have also 
metabolically labeled the JMAR cells with [S35]-methio-
nine and equal CPM from cell lysates and condition 
medium were immunoprecipitated with anti-S100A7 and 
separated by SDS-PAGE, further analysed by autoradi-
ography (Fig. 3b). Next we have collected saliva samples 
from head and neck cancer patients as immunoblotting 
was performed for the detection of S100A7 protein 
expression. As shown in Fig. 3c, 18 out of 37 (48.65) saliva 
samples from the head and neck cancer patients has very 
high level of S100A7, and other has in the detectable 
range. Only 5 out of 37 (13.5%) tumor samples showed no 
expression of S100A7 in saliva, indicating that 32 out of 
37 (86.5%) tumor samples showed expression of S100A7. 
On the other hand, we have analyzed four normal salivae, 
and S100A7 was absent in all four normal saliva samples. 
We were planning to examine more normal and head and 
neck cancer patient’s saliva for the detection of S100A7. 
Our present findings suggested that S100A7 can be uti-
lized as novel protein biomarker for clinical diagnosis 
and disease status of head and neck cancer.
siRNA of S100A7 reverses anoikis resistant JMAR cells 
to anoikis sensitive cells
We have transfected anoikis resistant JMAR cells with 
siRNA of S100A7, control empty vector and Tu167 cells 
both were grown in attached or detached conditions for 1 
or 2 days, and percentage of apoptotic cells were analyzed 
by flow cytometry. As shown in Fig.  4a, siRNA trans-
fected JMAR cells underwent 39% apoptosis while only 
14% cell death was observed in JMAR cells transfected 
with control vector after 24 h. After 48 h time point, 59% 
of JMAR cells transfected with siRNA showed apoptosis 
while only 12% of the control vector-transfected JMAR 
cells were apoptotic population. Apart from this 19% and 
34% cell death were observed for 24 and 48 h respectively 
in the parental cell line TU167. Protein lysates from the 
same conditions were analyzed for the psoriasin expres-
sion by immunoblot. As shown in the Fig.  4b, S100A7 
protein expression increased with the time interval, while 
Fig. 3 S100A7 is secreted out in the medium by the cells and as well as in saliva by the head and neck cancer. a Conditioned medium from 
attached (24 h) TU167 and JMAR were immunoprecipitated by S100A7 antibody and immunoblotted with S100A7. b Cells are labelled with [35S]-
methonine for 12 h in attach condition and cell lysates and condition medium containing equal CPM was immunoprecipitated with S100A7 anti-
body and analyzed by autoradiography. c Saliva from normal and head and neck cancer patient containing equal protein were analyzed by Western 
blot for the detection of S100A7.
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it was down-regulated in detached JMAR cells trans-
fected with siRNA.
Up‑regulation of S100A7 gene mediated by Akt 
phosphorylation signaling
To investigate whether cell detachment in anoikis resist-
ant cell line directly initiates survival signaling, as well as 
to recognize its downstream molecules, protein kinase 
B (PKB; also known as AKT) activity was first exam-
ined, which helps to prevent the development of anoikis 
[34, 35]. Under detached conditions, Akt is activated in 
anoikis resistance JMAR cell line (Fig.  4d). This result 
also demonstrates that, S100A7 is up-regulated dur-
ing cell detachment in anoikis resistance cell line that is 
mediated through the PKB survival pathway. This result, 
on the other hand, does not rule out the chance for the 
aggregate development which may further add to survival 
signaling in suspension. Significant PKB activation was 
observed in anoikis resistant cells. These phenomena sug-
gested that PKB pathway promotes anoikis resistance via 
triggering of S100A7 action. Certainly, inhibition of PKB/
PI3 K with specific agent LY294002 lead to inhibition of 
S100A7 mediated survival (Fig. 4c, d). From these obser-
vations, although it seems to be that PI3K/PKB signaling 
through S100A7 contributes to anoikis resistance, but 
more detailed understanding of the molecular mecha-
nisms by which S100A7 contributes to anoikis resistance 
of human cells, is necessary in order to develop molecu-
lar targets that reverses anoikis resistant.
S100A7 gene responsible for anoikis resistance in head 
and neck cancer
Further delineate the possible involvement of S100A7 
in cancer cells, we have next established stable TU167 
clones expressing different level of S100A7 (C1; clones 
expressing moderate level of S100A7, and C2; clones 
expressing higher level of S100A7) or control vector as 
observed by western and northern blot for the protein 
and RNA expression respectively (Fig.  5a, b). Later, we 
have also confirmed the expression of S100A7 protein by 
fluorescence microscopy (Fig.  5c). Next, we have grown 
the clones in both attached and detached condition for 
1 or 2 days and percentages of apoptotic cells were ana-
lyzed by flow cytometry. As shown in Fig. 5d that stable 
Fig. 4 siRNA of S100A7 transfected cells can down-regulate the expression of S100A7 protein level through AKT signaling. a Flow cytometric 
analysis of sub G0/G1 cell population of JMAR and Tu167 cells. b Western blotting of S100A7 protein in JMAR cells transfected with siRNA of S100A7. 
The JMAR cell line was pre-incubated with or without LY294002 for 24 h in suspension culture prior to determination of apoptotic fraction of cells 
by flow cytometry. c, d Phosphorylation of Akt and expression of S100A7 by western blot.
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clones of S100A7 were more anoikis resistant than the 
vector clones. Interestingly, we have observed that the 
C2 clones (higher level of S100A7) were more resist-
ant towards apoptosis as in detached condition than C1 
clones (moderate level of S100A7 expression), indicating 
the level of S100A7 as the quantitative indicator of devel-
oping anoikis resistance.
S100A7 gene responsible for tumorigenicity 
and metastatic potential in HNSCC
Here the probable reason of S100A7 expression for the 
growth features of HNSCC cells, which were calculated 
by the colony formation and cell proliferation rate. Over 
expression of S100A7 was escorted by a reproducible of 
the capability of cells to form outsized colonies in soft 
agar as differentiated with vector transfected control 
cells (Fig. 6a). Further assessment of the effect of choice 
for anoikis resistance on tumor development, it was 
calculated by the enlargement of the entire cell lines 
in an orthotopic tumor model [26]. In the subsequent 
experiment tumor formation and weight loss were 
observed in the athymic nude mice due to the tongues 
were injected with 1  ×  106 vector/C1 and C2 (sta-
ble clones of S100A7) cells. Further all the animals i.e. 
100% in all groups produced tumors, the rates of con-
tinued existence (animals were sacrificed till the body 
weight loss was found less than 25% from the starting 
experiment weight) variation was greatly observed. The 
midpoint survival for the C1 and C2 injected animals 
were 12 and 14  days respectively with all the animals 
dying at the end of the 25th day (Fig. 6b; Table 1). There 
was a significant difference between survival curve of 
both C1 (p < 0.0001) and C2 (p < 0.0001) with respect 
to the survival curve of mock-transfected TU167 clones 
injected in animals. Interestingly, there was also a sig-
nificant difference (p < 0.0001) in the survival curve of 
orthotopic generated tumor mice injected with clones 
C1 and C2, that was analyzed by log-rank (Mantel-
Cox) test. At the end of 25 days, hundred percentages 
of the mock-transfected TU167 injected animals were 
surviving with negligible mass loss, in spite of clini-
cally obvious and histologically confirmed tumor lump. 
Since revealed in Fig.  6c, the lump produced by these 
cell lines were morphologically different. Tumor for-
mation has taken place by the mock-transfected cells 
showing a number of controlled tumor colonies with 
minimal S100A7 staining while the C1 and C2 tumors 
confirmed a more diffusely infiltrative development 
model and over expression of S100A7. Together, these 
observations suggested that head and neck cancer cells 
expressing S100A7 have altered growth characteristics 
and tumorigenicity.
Fig. 5 Effect of S100A7 expression on anoikis in head and neck cancer cells. a Western blot analysis of vector and stable clones of S100A7 expres-
sion was moderate (C1) and higher (C2) level. The blot was reprobed with a β-actin as a loading control. b S100A7 mRNA expression in the stable 
clones. c Expression of S100A7 by immunofluorescence microscopy in the stable clones. d Detached cells were suspended in a 15 ml tube and 
rotated in the incubator at different time as described in the “Methods”, and flow cytometry assessed sub G0/G1 cells. Results shown are representa-
tive of three experiments.
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Conclusions
In summary, we provide new evidence that the S100A7 
is responsible for anoikis resistance and tumorigenic-
ity in human oral cancer cells and also positively con-
trols the growth rate of the human head and neck cancer 
cells. This conclusion is based on the following facts: (1) 
up-regulation of S100A7 mRNA and protein in anoikis 
resistant cell lines; (2) Expression of the S100A7 in an 
orthotopic tumor model of SCCOC; (3) Expression of the 
S100A7 in human head and neck cancer; (4) Secretion 
of S100A7 protein in conditioned medium by anoikis 
resistant head & neck cancer cell and in saliva of head 
and neck cancer patients; (5) Up-regulation of S100A7 
expression cells leads to an enhancement of the tumori-
genicity and anchorage-independent growth of head and 
neck cancer cells; (6) S100A7 is up-regulated during cell 
detachment through Akt phosphorylation and finally, (7) 
S100A7 is responsible for anoikis resistance in head and 
neck cancer cells. The main goal is to screen cancer at an 
early stage so that adequate precautions can be done for 
further clinical intervention. In addition, the scrutinizing 
tool should be enough non-invasive and economical to 
allow extensive application. A material that gets secreted 
from tumor tissue, but not secreted by non-tumor, can 
easily and inexpensively measurable in saliva, serum or 
urine can act as a model biomarker, since the cancer is 
identified very precisely, early and non-invasive man-
ner. Cancer is a varied illness, and it is very much doubt-
ful that a sole biomarker will identify all types of cancer 
from a particular organ with high specificity and sensi-
tivity. In fact, biomarker such as prostate-specific anti-
gen (PSA) that claim to be highly sensitivity and tends 
to have little specificity as they do not identify cancer by 
itself however it is a more in common practice. We noted 
that a large mass population screening is a very high pri-
ority for maintaining high specificity (low false-positive 
rates). Still a minute false-positive rate interprets into a 
huge figure of populations subjected to pointless expen-
sive diagnostic actions and mental tension. Therefore, 
biomarkers should be very much precise for cancer, and 
the application of quite a few such biomarkers of cancer 
would help the screening program very responsive and 
accurate. From our preliminary studies using immuno-
histochemistry and Western blotting of human oral can-
cer tumor and saliva specimens from cancer suffering 
Fig. 6 Effect of S100A7 expression on Soft agar colony formation and tumorigenicity of head and neck cancer cells. a Anchorage independent 
growth of TU167 cells stably transfected with different level of S100A7 expression i.e. C1 and C2 clones along with vector-transfected. Results 
were representative photographs of soft agar colonies (n = 3). b Survival curve of nude mice orthotopically implanted with vector (pcDNA3.1) or 
S100A7 clones (C1 and C2) tumors. Nude mice were orthotopically implanted in the tongue with 1 × 106 Vector or C1 or C2 S100A7 stable cells and 
observation showed weight loss with time. Animals losing more than 25% of their initial body weight were sacrificed. All the vector injected animals 
survived greater than 25 days without significant weight loss and therefore were sacrificed at that time point. c IHC of S100A7expression in FFPE 
tumor specimens from vector, C1, C2 orthotopically injected nude mice.
Table 1 Survival curve analysis using Kaplan–Meier sur-
vival test
Kaplan–Meier survival curve was plotted for three groups of mice receiving 
orthotropic tongue injection of (1) pcDNA3.1, (2) C1 and (3) C2 stable clones 
of TU167. P value was calculated by using log-rank (Mantel-Cox) test between 
mock (pcDNA3.1) vs. C1 or C2 groups.
TU167 clones Median survival (day) P value
pcDNA3.1 >25 or undefined
C1 (moderate S100A7 expression) 14 <0.0001
C2 (high S100A7 expression) 12 <0.0001
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patients and normal beings we have been noticed that 
a marker, S100A7 is being expressed in saliva, and tis-
sues of oral cancer patients but almost absent in normal 
saliva and adjacent normal tissue. In a prospective clini-
cal trial we will (1) measure the saliva levels of S100A7 
in patients with oral leukoplakia treated with chemopre-
vention approaches prior to during and after therapy and 
determine whether there is any association between sali-
vary S100A7 level and progression to oral cancer; and (2) 
measure the pre-treatment, immediate post-treatment 
and follow-up levels of salivary S100A7 to determine 
whether there is any association with the level of S100A7 
and local recurrence. The molecular mechanisms, by 
which S100A7 affects the anoikis of human cells, were 
not still clear at the moment. Our findings have clearly 
demonstrated for the first time a potential role of S100A7 
in anoikis and may be one of the early detection markers 
for head and neck cancer.
Methods
Reagents and cell line
TU167, JMAR, JMARC39, JMARC42 [33] and MDA-
MB-468 human cancer cell lines were used. All cell lines 
were grown and maintained in DMEM medium sup-
plemented with 10% fetal calf serum. For western blot 
analysis following primary and secondary antibodies 
were used: S100A7 (Imgenex Inc USA), β-actin (Sigma-
Aldrich, St. Louis, MO), Akt and phospho Akt (Cell Sign-
aling Technology, Danvers, MA) and anti- rabbit/mouse 
horseradish peroxidase-conjugated (Amersham, Piscata-
way, NJ).
Generation of resistant cell line
TU167 cells were trypsinized and collected in a venti-
lated 15 ml centrifuge tube and incubated for 72 h on a 
revolving shaker with 5% CO2 at 37°C. The survived cells 
were cultured to 80–90% confluency, and a similar proce-
dure was carried seven instances to produce the anoikis 
resistance JMAR cell line [36].
Generation of stable cell line and transient transfection
The full-length coding sequence of psoriasin [GenBank: 
AJ012825.1] was cloned into pcDNA3.1 [37] and trans-
fected into TU167 cells by Lipofectamine (Invitrogen, 
Burlington, ON, Canada). Stable clones were selected by 
zeocin, as a selection marker. Several clones were devel-
oped, and immunoblot determined protein expression 
of psoriasin. TU167-mock was generated by transfection 
with the empty vector. JMAR cells were also transfected 
with protein-specific siRNA (Qiagen, Mississauga, ON, 
Canada) of psoriasin. siRNA was conducted using Dhar-
mafect-4 reagent (Dharmacon).
Immunohistochemistry (IHC)
For Immunohistochemistry purpose, formalin-fixed tis-
sue samples were embedded in paraffin followed by sec-
tioning (5-µm) of the blocked tissue, which was collected 
from Department of Dentistry, Bankura Sammilani Med-
ical College, approved by Institutional Ethical Committee 
[approval number: PR-HC/6-119/2895(8)] Bankura Sam-
milani Medical College, Bankura, West Bengal 722101. 
IHC was performed with appropriate primary anti-
S100A7 antibody, positive and negative control was done 
simultaneously in the same experiments as previously 
described [38].
Western blot and immuno‑precipitation study
Protein was isolated from the cells using in NP-40 lysis 
buffer (Sigma-Aldrich, USA) for 60 min at 4°C. Proteins 
were separated in sodium dodecyl sulphate (SDS) poly-
acrylamide gel electrophoresis and transferred to nitro-
cellulose membrane. The Blocking of the Blots were done 
with Phosphate-buffered saline Tween (PBST) containing 
3% bovine serum albumin for 1 h and subsequently incu-
bated with the primary antibodies overnight at 4°C. After 
washing, blots were kept in secondary antibodies fol-
lowed by development of bands by ECL reagents (Sigma-
Aldrich, USA).The cells were metabolically labelled 
with 100  µCi/ml [35S]-methionine in methionine-free 
medium containing 2% dialyzed fetal bovine serum for 
4–8 h. Cell extracts containing same trichloroacetic acid 
perceptible counts and immunoprecipitated by S100A7 
antibody and resolved on SDS-PAGE and analyzed after 
exposure to film.
Immunoblot analysis of human tissue and saliva
Human oral tissue and saliva specimens were collected 
from the Department of Dentistry, Bankura Sammilani 
Medical College, Bankura, West Bengal 722101 approved 
by Institutional Ethical Committee [approval number: 
PR-HC/6-119/2895(8)], Bankura Sammilani Medical 
College. All patients agreed to participate in this study 
and signed written informed consent. Tissue samples 
were homogenized in tissue lysis buffer (Sigma-Aldrich, 
USA) and proteins were isolated and examined by west-
ern blot analysis [39].
Apoptosis assay
The determination of cell viability was done as 
described earlier [40]. Further, the flow cytometry was 
used to study the cell cycles (BD Corporation, Frank-
lin Lakes, NJ, and USA) and the measurements of the 
apoptotic percentage were considered from sub-G0/G1 
fraction. The data analysis was done by Cell Quest soft-
ware version 2.0 (BD).
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Soft agar colony formation assay
The bi-layer of soft agar assay was executed by seeding 
cells (2 × 104 cells/well) which were suspended in 1 ml 
of 0.36% bacto-agar, Further the suspension with 1  ml 
was layered with 0.6% agar medium base layer in 12-well 
plates and the incubation of cells were done at 37°C with 
5% CO2 for 3–4 weeks and needed every fifth day. After 
14–21 days, colonies >0.05 mm were stained with crystal 
violet (0.005%) as described previously [41].
Orthotopic animal model
Male athymic nude C57BL/6 mice of 6–10  weeks of age 
were accommodated in a particular pathogen-free animal 
facility, which were obtained from the All of the animal pro-
cedures were executed according to the guidelines approved 
by Department Of Biotechnology Institutional Animal Ethi-
cal Committee (approval no: E-1/MM-SMST/13), Indian 
Institute Of Technology, Kharagpur. Mice were divided into 
three groups (n = 10) namely pcDNA3.1, C1 (TU167 sta-
bly transfected with pcDNA3.1/S100A7 plasmid expressing 
intermediate level of S100A7), C2 (TU167 stably transfected 
with pcDNA3.1/S100A7 plasmid expressing high level 
of S100A7). The mouse received sub-mucosal injection 
of 1  ×  106 of either mock (pcDNA3.1 empty vector) or 
pcDNA3.1/S100A7 plasmid expressing intermediate level 
of S100A7 or pcDNA3.1/S100A7 plasmid expressing high 
level of S100A7 stably transfected TU167 cells (suspended 
in a volume of 50 μl) directly into anterior tongue using a 
1-ml syringe (Hamilton Co., Reno, Nevada) with a 30-gauge 
hypodermic needle. The injected animals were observed 
each alternative day for the growth of a lump on the tongue 
and mass loss were observed. CO2 inhalations were given 
for sacrificing the mice, when they had lost less than 25% of 
their pre-injection body weight [35].
Kaplan–Meier survival analysis
Kaplan–Meier survival analysis of different clones of 
S100A7 in orthotopic tongue model was plotted using 
Graph Pad Prism 5.0, and log-rank (Mantel-Cox) test was 
applied to find out the statistical significance between the 
groups.
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